CHMP January 2026 Approvals: Expanding Access t...

By João L. Carapinha

February 2, 2026

CHMP January 2026 Approvals Signal Expanded Access to Innovative Therapies The
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Translational Medicine Portugal: Driving Collaborative Innovations in Healthcare
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
GLP-1RAs Psychiatric Care: Transforming Metabolic Management for Psychotropic...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine a...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascul...